Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Yangfeng Li ; Zhengnan Shen ; Kiira Ratia , et al. JMC,2024,67(4):2712-2731. DOI: 10.1021/acs.jmedchem.3c01837
More
Abstract: The bromodomain and extra-terminal domain (BET) proteins are epigenetic readers, regulating transcription via two highly homologous tandem bromodomains, BD1 and BD2. Clinical development of nonselective pan-BD BET inhibitors has been challenging, partly due to dose-limiting side effects such as thrombocytopenia. This has prompted the push for domain-selective BET inhibitors to achieve a more favorable therapeutic window. We report a structure-guided drug design campaign that led to the development of a potent BD1-selective BET inhibitor, 33 (XL-126), with a Kd of 8.9 nM and 185-fold BD1/BD2 selectivity. The high selectivity was first assayed by SPR, validated by a secondary time-resolved fluorescence energy transfer assay, and further corroborated by BROMOscan (~57–373 fold selectivity). The cocrystal of 33 with BRD4 BD1 and BD2 demonstrates the source of selectivity: repulsion with His437 and lost binding with the leucine clamp. Notably, the BD1 selectivity of BET inhibitor 33 leads to both the preservation of platelets and potent anti-inflammatory efficacy.
Purchased from AmBeed: 910543-72-5 ; 56-84-8 ; 71-00-1 ; 944937-53-5 ; 1793016-39-3 ; 50618-82-1
CAS No. : | 71-00-1 | MDL No. : | MFCD00064315 |
Formula : | C6H9N3O2 | Boiling Point : | No data available |
Linear Structure Formula : | - | InChI Key : | - |
M.W : | 155.15 | Pubchem ID : | - |
Synonyms : |
|
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | |
Hazard Statements: | H315-H319-H335 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
61% | In water; at 0 - 45℃; for 4h; | (1) Add 15.15 g of L-histidine in 100 ml of water,Add 20g D,L-<strong>[41360-32-1]sulfophenylacetic acid</strong>,The temperature was raised to 45 ° C, the reaction was stirred for 2 hours; the temperature was slowly lowered to 0 ° C to 10 ° C, and the crystallization was stirred for 2 hours;Filtration, washing the filter cake with appropriate amount of cold ethanol to obtain 21 g of D(-)-<strong>[41360-32-1]sulfophenylacetic acid</strong> histidine, the yield is 61.0percent; |
[ 645-35-2 ]
(S)-2-Amino-3-(1H-imidazol-4-yl)propanoic acid hydrochloride
Similarity: 0.98
[ 584-85-0 ]
(S)-2-(3-Aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl)propanoic acid
Similarity: 0.69